IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas

Arianna Di Napoli1 · Daniele Greco2 · Giorgia Scafetta1 · Francesca Ascenzi3 · Alessandro Gulino2 · Luigi Aurisicchio4 · Fabio Santanelli Di Pompeo5 · Adriana Bonifacino6 · Enrico Giarnieri7 · John Morgan8 · Rita Mancini3 · Marshall E. Kadin8

Received: 23 July 2020 / Accepted: 20 October 2020 © The Author(s) 2020

Abstract

Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is an uncommon peripheral T cell lymphoma usually presenting as a delayed peri-implant effusion. Chronic inflammation elicited by the implant has been implicated in its pathogenesis. Infection or implant rupture may also be responsible for late seromas. Cytomorphological examination coupled with CD30 immunostaining and eventual T-cell clonality assessment are essential for BI-ALCL diagnosis. However, some benign effusions may also contain an oligo/monoclonal expansion of CD30+ cells that can make the diagnosis challenging.

Since cytokines are key mediators of inflammation, we applied a multiplexed immuno-based assay to BI-ALCL seromas and to different types of reactive seromas to look for a potential diagnostic BI-ALCL-associated cytokine profile. We found that BI-ALCL is characterized by a Th2-type cytokine milieu associated with significant high levels of IL-10, IL-13 and Eotaxin which discriminate BI-ALCL from all types of reactive seroma. Moreover, we found a cutoff of IL10/IL-6 ratio of 0.104 is associated with specificity of 100% and sensitivity of 83% in recognizing BI-ALCL effusions. This study identifies promising biomarkers for initial screening of late seromas that can facilitate early diagnosis of BI-ALCL.

Keywords BI-ALCL · Cytokines · Seroma · Diagnosis

Abbreviations

BDNF Brain-derived neurotrophic factor
BI-ALCL Breast implant-associated anaplastic large-cell lymphoma
CCL5 (RANTES) Chemokine C–C motif ligand 5
EGF Epidermal growth factor
FGF2 Fibroblast growth factor

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00262-020-02778-3) contains supplementary material, which is available to authorized users.

Published online: 04 November 2020
seromas than in benign seromas. IL-13, IL-22, and/or IFN-

have been detected in malignant tumors more frequently compared to their expression in lymphocyte-rich benign seromas. 

Recently, higher levels of soluble interleukin (IL) 9, IL-10, IL-1, IL-2, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IFN-γ-inducible protein 10 (IP-10, CXCL10), 

**Introduction**

Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a provisional entity recently introduced in the revised version of the WHO classification of lymphoid malignancy [1]. Most patients experience a late-onset peri-prosthetic effusion (seroma) as the first manifestation of the disease [2]. Aspirated effusions must undergo microbiological culture, cytological analysis, immunocytochemistry for CD30 expression and sometimes analysis of T-cell receptor genes rearrangement to confirm clonality of the T-cell population. This approach allows an early diagnosis and avoids local and lymph node metastasis of tumor cells [3]. Nevertheless, most late seromas are benign and related to infection, trauma or implant rupture [4]. Also, selected cases presenting with a suspicious clinical history, negative culture and cytology and positive molecular test may be difficult to classify [5, 6]. Indeed, some reactive inflammatory responses may be associated with a T-cell oligo-monoclonal expansion that may make the diagnosis even more challenging. Hanson et al. reported on a CD30 enzyme-linked immunosorbant assay for the rapid detection of breast implant-associated anaplastic large-cell lymphoma [7]. However, a major limitation to the assay is represented by CD30+ reactive T cells being potentially detected in lymphocyte-rich benign seromas [5, 6]. Recently, higher levels of soluble interleukin (IL) 9, IL-10, IL-13, IL-22, and/or IFN-γ have been detected in malignant seromas than in benign seromas [8]. This prompted us to further validate these results and to investigate the existence of a possible BI-ALCL-associated cytokine signature by applying a highly multiplex immuno-based assay to late seromas, including, besides BI-ALCL, different types of reactive effusions.

**Methods**

**Samples**

Late peri-implant breast seromas aspirated by ultrasound-guided fine-needle aspiration (US-FNA) and sent for cytological analysis were centrifuged and supernatants were collected and stored at -80 °C. Cell pellets were immediately used for smear and cell block preparation. Based on morphological and immunohistochemical analyses, the seromas were diagnosed as malignant (12 BI-ALCL samples) or benign (20 samples). The latter were further sub-classified as acute-type (6 samples), mixed-type (6 samples) and chronic-type (8 samples) as previously reported [5]. All patients with BI-ALCL were women and had textured implants placed either for reconstructive (6 patients) or cosmetic indication (6 patients); their ages ranged from 35 to 76 years (mean, 55 years), and time from implantation to seroma development ranged from 4 to 15 years (mean, 8.6 years). Also, evaluated were supernatants of 7 T-cell lymphoma cell lines (T-LCL), derived from clinical cases of BI-ALCL (TLBR-1, -2, -3, -4) [9], cutaneous T cell lymphoma lines (Mac-1, Mac-2A established by MEK) and an ALK-positive systemic ALCL (Karpas 299) obtained from DSMZ German Collection of Microorganisms and cell cultures GmbH.

**Cytokine detection**

The Human ProcartaPlex Cytokine/Chemokine/Growth Factor 45-plex immunoassay kit (Invitrogen by Thermo Fisher Scientific) was adopted to simultaneously analyze the concentrations of 45 different cytokines in the supernatant of 32 late seromas and of 7 cell lines following the manufacturer’s recommendations, in a Luminex Instrument system. Samples were run in duplicate as undiluted and diluted to 1:20 in phosphate-buffered saline (PBS) and compared to a standard curve. The 45 cytokines and growth factors included: brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), Eotaxin, fibroblast growth factor (FGF2), granulocyte-macrophage colony stimulating factor (GM-CSF), growth-related oncogene protein-α (GRO-α), hepatocyte growth factor (HGF), interferon-α (IFN-α), IFN-γ, interleukin 1 receptor antagonist (IL-1RA), IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IFN-γ-inducible protein 10 (IP-10, CXCL10),

| GM-CSF | Granulocyte–macrophage colony stimulating factor |
|--------|---------------------------------------------|
| GRO-α  | Growth-related oncogene protein-α |
| HGF    | Hepatocyte growth factor |
| IFN-α, IFN-γ | Interferon-α, -γ |
| IL-10, IL-6 | Interleukin 10, -6 |
| IL-1RA | Interleukin 1 receptor antagonist |
| IP-10, CXCL10 | IFN-γ-inducible protein 10 |
| LIF    | Leukemia inhibitory factor |
| MCP-1  | Monocyte chemotactic protein 1 |
| MIP-1β (CCL4), MIP-1α | Macrophage inflammatory protein type 1β, 1α |
| PIGF-1 | Placenta growth factor 1 |
| RS     | Reactive seromas |
| SCF    | Stem cell factor |
| SDF-1α | Stromal cell-derived factor 1 |
| TNF-α, TNF-β | Tumor necrosis factor-α |
| VEGF-A, VEGF-D | Vascular endothelial growth factor-A, -D |

 Springer
leukemia inhibitory factor (LIF), monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein type 1β (MIP-1β, CCL4), MIP-1α, NGF-β, chemokine (C–C motif) ligand 5 (CCL5, RANTES), platelet-derived growth factor-BB (PDGF-BB), placenta growth factor 1 (PIGF-1), stem cell factor (SCF), stromal cell-derived factor 1 (SDF-1α), tumor necrosis factor-α (TNF-α), TNF-β, vascular endothelial growth factor-A (VEGF-A), and VEGF-D.

Data analysis

The expression levels of the 45 different cytokines assessed were compared among the samples using the averaged median fluorescent intensity (MFI) values obtained by the average of undiluted and diluted samples. Hierarchical clustering analysis (HCA) was performed using Spearman correlation distance and Ward.D2 linkage criterion [10] (implemented in the ‘hclust’ function (R package ‘stats’). Dendrogram and heatmap were generated using the ‘ComplexHeatmap’ package (version 2.2.0) (R package ‘stats’) [11]. To investigate misplaced samples with respect to clinical classification, multidimensional scaling (MDS) was performed using the ‘cmdscale’ function (R package ‘stats’) retaining only the first three principal coordinates (explained variance: 70.4%) and a 3D plot generated using the ‘plot3D’ (version 1.3) (R package ‘stats’) (https://cran.r-project.org/package=plot3D).

Differential analysis of cytokine concentration was conducted on the log2 transformed MFI values using a moderated t-test [12] implemented in the ‘limma’ R package (version 3.42.2. Bioconductor version: release 3.1) [13]; p values were corrected for multiple testing applying the Benjamini–Hochberg procedure [14]; a leave-one out strategy was implemented to assess the robustness of differentially expressed genes in a given group comparison by counting the number of times a cytokine is differentially expressed (p < 0.01) removing any one sample from the dataset. Volcano plots, representing the distribution of the fold changes (difference of means, log2 scale, x-axis) and p-values (BH-adjusted, -log10 scale, y-axis) for each comparison, were generated using the ‘plot’ function (R package ‘graphics’).

Group comparisons based on the mean absolute concentration levels for selected cytokines IL-10, Eotaxin, IL-13, IL-6, and IL-10/IL-6 ratio were again assessed by the means of moderated t-test, using the ‘limma’ R package.

The ability of IL-10, Eotaxin, IL-13 and IL-6 cytokine levels (pg/mL) and of IL-10/IL-6 ratio to identify BI-ALCL was investigated by receiver-operator characteristic (ROC) curves, including the computation of sensitivity, specificity, optimal cut-off values (Youden index), area under the curve (AUC), 95% confidence interval (CI), using the ‘pROC’ (version 1.16.2) R package [15].

All statistical analyses were performed in R version 3.6.2 (https://www.r-project.org), using RStudio IDE version 1.2.1322 (https://www.rstudio.com/).

Establishment of primary cell culture of BI-ALCL and xenotransplantation into NGS mice

Primary tumor cells derived from seromas of three patients diagnosed with BI-ALCL at Sant’Andrea Hospital, Roma, Italy were maintained in suspension culture in a complete medium (RPMI-1640 with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin) supplemented with 50 IU/mL of recombinant IL-2 (R&D Systems). After two weeks, 2.5 × 10^6 viable primary tumor cells derived from the 3 patients, were injected subcutaneously in the right flank of three six-week-old female NOD.Cg-Prkdcsid Il2rtm1Wjl/SzJ mice (NSG; Charles River). Before injection, cells were washed once in PBS and the cell pellet was resuspended in Matrigel solution (SIGMA). NGS mice are severely immunodeficient due to the lack of mature B, T, NK cells and IL-2 signaling. After one week of acclimation, mice were housed in a plastic cage and fed on standard diet with water ad libitum, in an animal facility controlled at a temperature of 23 ± 2 °C, 60 ± 5% humidity, and with a 12 h light and dark cycle.

One of these primary cell lines was tumorigenic in the NGS mouse and after 83 days from injection, a discrete tumor mass was palpable. Tumor growth was monitored weekly by caliper measurement and tumor volume was determined by the formula (D × d)^2/2, where D was the longest diameter of the tumor. The animal was euthanized by cervical dislocation when severe signs of suffering were observed. At sacrifice, a complete necropsy procedure was performed. No tumor cells were found in lymph nodes, lungs, liver or spleen. The subcutaneous tumor mass measured 8.49 mm × 7.87 mm (volume = 263 mm^3), its weight was 160.4 mg and after removal, it underwent histopathological examination.

RNAscope validation of selected cytokines

Cytokine mRNA production of IL6 and IL10 was further investigated by RNA in situ hybridization (ISH) using RNAscope technology. The RNAscope assay was applied to cell block paraffin sections of late seromas as previously described [16, 17]. Briefly, FFPE Sects. 2 μm thick were deparaffinized in xylene and then hydrated in an ethanol series. Hybridization was with target probes: Probe-Hs-IL6 and Probe-Hs-IL10. The preamplifier, amplifier, label probe, and chromogenic detection procedures were performed according to the manufacturer’s instructions (RNAscope® 2.0 HD Reagent Kit, Advanced Cell Diagnostics, Newark CA, USA).
For double staining, RNAscope assay for IL6 and IL10 was performed first and followed by immunohistochemistry for CD30 (clone Ber-H2, dilution 1:50) (Dako, Denmark). Staining was revealed using Super Sensitive Link Label IHC Detection System Alkaline Phosphatase (BioGenex, Fremont, CA, USA). Vulcan Fast Red Chromogen Kit 2 (BioCare Medical, Pacheco, CA, USA) was used as substrate-chromogens, followed by counterstaining with Harris hematoxylin.

**Immunohistochemistry**

Immunohistochemistry for GATA3 (clone L50-823, Cell Marque, Rocklin, CA) and FoxP3 (clone 236A/E7, Abcam, UK) was performed on 2 µm thick formalin-fixed paraffin-embedded (FFPE) tissue sections of a BI-ALCL seroma cell block and of a BI-ALCL xenograft using an automated immunostainer (Omnis, Agilent Technologies, USA). Tissue sections were pretreated using EnVisionTM FLEX Target Retrieval Solution (Agilent) and incubated with an optimal dilution of the primary antibody. The reaction was visualized with the EnVision Detection Kit (Agilent) using 3–3’-diaminobenzidine chromogenic substrate. Sections were counterstained with EnVision FLEX Hematoxylin (Link) (Agilent).

**Results**

**BI-ALCL has a distinct cytokine profile with significantly higher levels of IL-10, IL-13, Eotaxin TNFβ and RANTES compared to benign reactive effusions**

We simultaneously analyzed the concentrations of 45 different cytokines, chemokines and growth factors in the supernatant of 32 late seromas, including 12 BI-ALCL and 20 benign reactive seromas (RS), and in the supernatant of 7 T-cell lymphoma cell lines (T-TCL) using a multiplex assay. Based on the cellular composition of the inflammatory infiltrate, the RS were categorized as acute-type \( (n=6) \) when neutrophils represented >50% of the total cellularity, mixed-type \( (n=6) \) when composed of a variable amount of neutrophils (ranging from 5 to 50% of the total cellularity), monocytes and lymphocytes, and chronic-type \( (n=8) \) when composed mainly by lymphocytes, monocytes and by sporadic polymorphonuclear granulocytes, mainly eosinophils (<5% of the total cellularity), as previously reported [5]. First, we conducted an unsupervised clustering analysis of the cytokine levels in the different samples. Strikingly, BI-ALCL, RS, and T-TCL appeared clearly distinct in both unsupervised analyses.

![Fig. 1 Unsupervised analyses of 45 cytokine levels in late seromas and T cell-lymphoma cell lines](image)

(T-LCL). Reactive seromas were further subclassified as acute (RS-A, \( n=6 \)), mixed (RS-M, \( n=6 \)) and chronic-type (RS-C, \( n=8 \)). Cytokine profiles of BI-ALCL, RS and T-LCLB appeared clearly distinct in both unsupervised analyses.
differentially expressed cytokines ($p < 0.001$) IL-10, IL-13, Eotaxin, IL-9, TNFβ and RANTES (Fig. 2a). Among these, only IL-10, IL-13 and Eotaxin remained significantly more expressed in BI-ALCL when compared to each of the three different types of RS (acute, mixed and chronic) (Fig. 2b–d). Of note, IL-6 was not differentially represented in BI-ALCL versus RS. To assess the robustness of the genes found to be differentially expressed, we conducted a leave-one-out (LOO) analysis for each comparison (i.e. BI-ALCL versus RS-A, BI-ALCL versus RS-C, and BI-ALCL versus RS-M) by leaving out one sample each time and counting the number of times each cytokine was differentially expressed ($p < 0.01$). We considered robust only those cytokines differentially expressed in spite of the removal of any one sample in the dataset. Overall, we observe that only Eotaxin, IL-10 and IL-13 result robust in all the three comparisons (Fig. 3a–c), making them good candidates for distinguishing BI-ALCL from any types of benign seroma.

We then compared BI-ALCL to T-LCL and the most significant differentially expressed cytokines were: Eotaxin, MCP1, IL-1RA and SCF (Fig. 2f). The same result was obtained when BI-ALCL clinical samples were compared to TLBR cell lines only, which are established cell lines derived from BI-ALCL samples [9] (Fig. 2g). These results may suggest that in BI-ALCL seromas Eotaxin, MCP1, IL-1RA and SCF might be produced at higher levels by the neoplastic cells or, alternatively, by the non-neoplastic cells (i.e. lymphocytes and monocytes) present in the microenvironment. The latter hypothesis is further supported by the comparison of T-LCL to RS. Indeed, among the cytokines more abundant in RS, there were Eotaxin, MCP1, IL-1RA, and SCF whereas among those produced by T-LCL, there were IL-13, RANTES, TNFβ, IL-22, and IL-9 (Fig. 2e). Interestingly, in contrast to what we observed for BI-ALCL, T-LCL were not characterized by higher levels of IL-10 compared to RS. This diversity could be related to the lack of an microenvironmental priming effect on tumor cells under in vitro growth conditions of stabilized lymphomatous cell lines, which should be considered as a limitation to their translational use.

No significant differences were found upon comparison of acute (RS-A) versus mixed (RS-M) or chronic (RS-C) type effusions (Fig. 2h–i). Whereas, MCP1, MIP1α, IL-1RA, HGF, RANTES, IL-9, IL-18 and MIP1β were found to be significantly more abundant ($p < 0.05$) in chronic compared to mixed-type seromas (Fig. 2j).

**IL-10, IL-13 and Eotaxin concentrations and IL-10/IL-6 ratio are candidate biomarkers for early detection of BI-ALCL**

Based on the median fluorescent intensity (NetMFI) values obtained by the multiplex analysis, the concentration of IL-10, IL-13, Eotaxin and IL-6 was calculated for each sample in undiluted samples (Table 1). Mean IL-10, IL-13 and Eotaxin levels were significantly higher in patients with BI-ALCL than in patients with reactive seromas ($p < 0.001$). In particular, in patients with BI-ALCL, the mean concentration levels were for IL-10: 2601.06 pg/mL (range 58.36–6950), for IL-13: 1403.69 pg/mL (range 68.64–4950.67), for Eotaxin: 668.49 pg/mL (range 424.98–954.65), and for IL-6: 7965.87 pg/mL (range 159.81–42,900), whereas in patients with reactive seromas, the mean concentration levels were for IL-10: 3.82 pg/mL (range 0.35–19.69), for IL-13: 12.97 pg/mL (range 0.83–67.45), for Eotaxin: 179.54 pg/mL (range 0.31–671.47), and for IL-6: 5732.97 pg/mL (range 6.12–42,900).

We then calculated the ability of these cytokines to identify BI-ALCL among all types of seromas using a receiver operating characteristic curve (ROC) (Fig. 4a–c). ROC curves showed that a cutoff of 39.03 pg/mL for IL-10 and of 68.05 pg/mL for IL-13 was both associated with sensitivity (Se) of 100% and specificity (Sp) of 100% (Youden index = 1), whereas a cutoff of 398.27 pg/mL for Eotaxin was associated with sensitivity (Se) of 100% and specificity (Sp) of 85% (Youden index = 0.94). ROC curve for IL-6 shows the poor performance of IL-6 as a diagnostic biomarker in identifying patients with BI-ALCL (Fig. 4d).

Based on these results, both IL-10 and IL-13 concentrations appeared as the best diagnostic biomarkers for BI-ALCL. However, since the same cytokine measurement could be affected by different techniques not calibrated to the same international standards [18], we tested the performance of an approach based on the adoption of ratios among paired cytokine levels. Interestingly, the IL-10-to-IL-6 ratio was among the most significant (logFC > 4; $p < 0.001$) (Supplementary Table 1). This result was of particular relevance since the IL-10/IL-6 ratio is currently being used for the diagnosis of another effusion-lymphoma e.g. the diffuse B-cell lymphoma of the vitreous [18]. In addition, IL-6 was considered a good denominator because it is a pro-inflammatory cytokine detectable in all seromas [8]. We then repeated the differential analysis looking for any cytokine produced in comparison to IL-6 in the different conditions (Fig. 5a–j) and, again IL-10 stood out as the most significant one in BI-ALCL *versus* RS (Fig. 5a). This was further confirmed when BI-ALCL was compared to the three different types of RS (Fig. 5b–d). In contrast, the IL-10-to-IL-6 ratio did not appear significant in the comparison of T-LCL to RS or to BI-ALCL (Fig. 5e, f).

We then evaluated the potential of the IL-10/IL-6 ratio to identify BI-ALCL samples. In our sample cohort, the mean level of IL-10/IL-6 was 3.04 (range 0.01–20.43) in BI-ALCL and 0.02 (range 0–0.10) in reactive seromas (Table 1). The ROC curve (Fig. 4e) showed that IL-10-to-IL-6 ratio higher than 0.104 was associated with a Se of 83% and a Sp of 100%...
the samples with a lower number of FOXP3 nuclei and prominent nucleoli encircling central necrotic areas consisted of pleomorphic tumor cells with highly atypical features. The BI-ALCL seroma and in the BI-ALCL xenograft, which were found in the cytoplasm of CD30-positive cells in both the antigenic stimulus and on the functional commitment of the cell being stimulated [26]. Using a multiplex protein assay, we demonstrated that BI-ALCL has a distinctly different cytokine profile when compared with different types of benign seromas characterized by high levels of IL-10, IL13, Eotaxin, IL9, TNFβ and RANTES. IL-13 and IL-9 are Th2 cell-associated cytokines [27]. In particular, IL-13 plays a key role in asthma, allergy, fibrosis and other pathological processes sustained by eosinophils [28, 29] whereas IL-9, initially described as T cell growth factor, is a pleiotropic cytokine linked to tumor immunity, immunity to pathogens, allergy, and autoimmune disease [30]. In addition to Th9 cells, Th2 and Th17 cells as well as induced Foxp3 + regulatory T cells (iTregs) cells also produce IL-9 [31, 32]. Of note, IL-9 has been demonstrated to be an autocrine growth factor in systemic ALK + ALCL [33]. Furthermore, IL-9 secreted by Hodgkin’s Reed Sternberg cells has been implicated in the recruitment of eosinophils in the classical Hodgkin Lymphoma microenvironment [34]. Eotaxin-1 (CCL11) and RANTES (CCL5) are also implicated in the recruitment of eosinophils into inflammatory sites during allergic reactions [35, 36]. Our data show high levels of Eotaxin in BI-ALCL but not in T-cell lymphoma cell lines supporting the hypothesis that it is secreted by normal cells of the microenvironment, activated by tumor cells. Similarly, CHL cells do not express eotaxin but produce IL-13 and TNF-α which induce eotaxin expression in co-cultured dermal fibroblasts [37]. Although eosinophils are not a constant feature, they are variably present in BI-ALCL (Supplementary Fig. 1) [19, 38]. TNF-β, also known as lymphotoxin alpha (LTr), in addition to promoting lymphoid tissue development, contributes to the effector responses of both the innate and the adaptive immune systems. Although data indicate that LT might be essential for Th2 cell development, it is traditionally regarded as a hallmark cytokine in Th1 cell responses [39, 40]. IL-10 may participate in mediating and/or regulating the functions of Th2 cells [41], but it is mainly...
Fig. 3 Leave-one out differential expression analysis. For each comparison BI-ALCL vs RS-A (12 BI-ALCL samples, 6 RS-A samples) (a); BI-ALCL vs RS-M (12 BI-ALCL samples, 6 RS-M samples) (b) and BI-ALCL vs RS-C (12 BI-ALCL samples, 8 RS-C samples) (c) the histograms report the number of times a cytokine is differentially expressed ($p < 0.01$) removing any one sample from the dataset. Only cytokines differentially expressed ($p < 0.001$) in at least one leave-one-out round are shown.

Table 1 IL-10, IL-13, Eotaxin and IL-6 measurements in late peri-implant breast seromas

|                       | Mean ± SD (pg/mL) | Range (pg/mL) | $p$ value |
|-----------------------|-------------------|---------------|-----------|
| **IL-10**             |                   |               |           |
| BI-ALCL               | 2601.06 ± 2284.90 | 58.36 – 6950  | BI-ALCL vs RS-All $p < 0.001$ |
| RS-All                | 3.82 ± 4.53       | 0.35 – 19.69  | BI-ALCL vs RS-A $p < 0.001$ |
| RS-A                  | 3.34 ± 2.81       | 1.46 – 8.40   | BI-ALCL vs RS-M $p < 0.001$ |
| RS-C                  | 4.04 ± 2.72       | 0.48 – 7.86   | BI-ALCL vs RS-C $p < 0.001$ |
| RS-M                  | 4.01 ± 7.71       | 0.35 – 19.69  | BI-ALCL vs T-LCL $p = 0.002$ |
| T-LCL                 | 1136.43 ± 2582.54 | 0.38 – 6950   | T-LCL vs RS-All $p = 0.003$ |
| **IL-6**              |                   |               |           |
| BI-ALCL               | 7965.87 ± 12,041.76 | 159.81 – 42,900 | BI-ALCL vs RS-All $p < 0.001$ |
| RS-All                | 5732.29 ± 10,539.82 | 6.12 – 42,900 | BI-ALCL vs RS-A $p = 0.733$ |
| RS-A                  | 7141.83 ± 7699.36 | 1353.45 – 19,149.33 | BI-ALCL vs RS-M $p = 0.022$ |
| RS-C                  | 3378.96 ± 5746.51 | 6.12 – 16,904.51 | BI-ALCL vs RS-C $p = 0.059$ |
| RS-M                  | 7460.54 ± 17,372.17 | 7.42 – 42,900 | BI-ALCL vs T-LCL $p = 0.435$ |
| T-LCL                 | 14,052.88 ± 19,822.55 | 4.19 – 42,900 | T-LCL vs RS-All $p = 0.674$ |
| **IL-13**             |                   |               |           |
| BI-ALCL               | 1403.69 ± 1367.37 | 68.64 – 4950.67 | BI-ALCL vs RS-All $p < 0.001$ |
| RS-All                | 12.97 ± 16.62     | 0.83 – 67.45  | BI-ALCL vs RS-A $p < 0.001$ |
| RS-A                  | 5.72 ± 6.51       | 0.83 – 17.86  | BI-ALCL vs RS-M $p < 0.001$ |
| RS-C                  | 23.52 ± 21.83     | 3.37 – 67.45  | BI-ALCL vs RS-C $p < 0.001$ |
| RS-M                  | 6.14 ± 6.56       | 3.37 – 19.53  | BI-ALCL vs T-LCL $p < 0.001$ |
| T-LCL                 | 5488.42 ± 6166.29 | 1.31 – 13,800.00 | T-LCL vs RS-All $p = 0.610$ |
| **Eotaxin**           |                   |               |           |
| BI-ALCL               | 668.49 ± 154.72   | 424.98 – 954.65 | BI-ALCL vs RS-All $p < 0.001$ |
| RS-All                | 179.54 ± 216.96   | 0.31 – 671.47 | BI-ALCL vs RS-A $p < 0.001$ |
| RS-A                  | 184.72 ± 239.00   | 20.69 – 654.35 | BI-ALCL vs RS-M $p < 0.001$ |
| RS-C                  | 238.58 ± 252.77   | 17.90 – 671.47 | BI-ALCL vs RS-C $p < 0.001$ |
| RS-M                  | 95.65 ± 135.08    | 0.31 – 358.65 | BI-ALCL vs T-LCL $p < 0.001$ |
| T-LCL                 | 5.73 ± 6.55       | 1.36 – 19.64  | T-LCL vs RS-All $p < 0.001$ |
| **IL-10/IL-6 RATIO**  |                   |               |           |
| BI-ALCL               | 3.04 ± 6.04       | 0.01 – 20.43  | BI-ALCL vs RS-All $p < 0.001$ |
| RS-All                | 0.02 ± 0.03       | 0 – 0.10      | BI-ALCL vs RS-A $p < 0.001$ |
| RS-A                  | 0.001 ± 0.002     | 0 – 0.01      | BI-ALCL vs RS-M $p = 0.002$ |
| RS-C                  | 0.03 ± 0.04       | 0 – 0.09      | BI-ALCL vs RS-C $p = 0.001$ |
| RS-M                  | 0.03 ± 0.04       | 0.001 – 0.10  | BI-ALCL vs T-LCL $p = 0.081$ |
| T-LCL                 | 3.29 ± 8.14       | 0 – 21.73     | T-LCL vs RS-All $p = 0.274$ |
produced by Tregs (i.e. thymus-derived Tregs and induced Tregs) to quench pro-inflammatory responses of both innate and adaptive immune cells preventing excessive tissue damage caused by bacterial and viral infections [42]. From our previous gene expression profiling data, a higher level of IL-10 mRNA emerged in BI-ALCL as compared to normal CD4+ T cells [20]. Herein we further demonstrated that the production of IL-10 in BI-ALCL is predominantly intrinsic to CD30-positive tumor cells, as shown by in situ hybridization data on seroma and xenograft.

Altogether, the abundance of IL-10, IL-13, IL-9, Eotaxin, Rantes and TNF-α and the frequent expression of GATA3 and FoxP3 transcription factors by neoplastic cells suggest that in BI-ALCL, a skewing towards Th2 and Treg cells occurs. We may postulate that in BI-ALCL pathogenesis, the implant may have elicited a Th2-type response with accumulation of T cells, mast cells, monocytes and eosinophils and that, also consequently to the activation of the STAT3 pathway, IL-10-producing Tregs may eventually be recruited or induced as a feedback mechanism. We have previously shown that gene expression profiling and immunohistochemical data suggest either activation-induced FoxP3 expression or a T helper-like regulatory T-cell status in a proportion of BI-ALCL with the upregulation of RORC, IL17A genes and of FoxP3 protein (20). Several reports also suggest that there is plasticity between Th2 cells and iTregs [43], which would be in keeping with our findings. In addition, evidence suggests that Tregs in the periphery can become unstable and dampen Foxp3 expression, adopting

![Fig. 4](image-url)

**Fig. 4** Receiver-operator characteristic (ROC) curves of IL-10, IL-13, Eotaxin and IL-6 cytokine concentrations and of IL-10/IL-6 ratio. Optimal cut-off values (Youden Index) are marked in red. IL-10: sensitivity (Se) 100%, specificity (Sp) 100% at 39.03 pg/mL (AUC. 1.00; 95% CI. 1.00–1.00) (a); IL-13: sensitivity (Se) 100%, specificity (Sp) 100% at 68.05 pg/mL (AUC. 1.00; 95% CI. 1.00–1.00) (b); Eotaxin: sensitivity (Se) 100%, specificity (Sp) 85% at 398.27 pg/mL (AUC. 0.94; 95% CI. 0.86–1.00) (c); IL-6: sensitivity (Se) 75%, specificity (Sp) 65% at 1881.91 pg/mL (AUC. 0.66; 95% CI. 0.47–0.85) (d); IL-10/IL-6: sensitivity (Se) 83%, specificity (Sp) 100% at 0.10 (AUC. 0.94; 95% CI. 0.86–1.00) (e). AUC area under the curve and CI confidence interval
Cancer Immunology, Immunotherapy

A

B

C

D

E

F

G

H

I

J

T-LCL vs RS, any / IL-6 ratio

RS-A vs RS-C, any / IL-6 ratio

Bi-ALCL vs T-LCL, any / IL-6 ratio

Bi-ALCL vs RS-A, any / IL-6 ratio

Bi-ALCL vs RS-M, any / IL-6 ratio

Bi-ALCL vs RS-C, any / IL-6 ratio

Bi-ALCL vs RS, any / IL-6 ratio

Bi-ALCL vs TLR, any / IL-6 ratio
some effector functions but still producing high amounts of IL-10 [44].

One important element of this study consists in the comparison of the BI-ALCL-associated cytokine milieu with that of the three different types of reactive effusions (i.e. acute, chronic and mixed), which revealed that high levels of IL-10, IL-13 and Eotaxin are able to differentiate BI-ALCL from all types of benign seromas. Moreover, IL-10/IL-6 ratio higher than 0.1 identified 10 out of 12 BI-ALCL, which means that 83 out of 100 seromas would be correctly classify as BI-ALCL. These findings are similar to what observed in primary central nervous system lymphoma (PCNSL) and in primary vitreoretinal lymphoma (PVRL, a subtype of PCNSL), in which the uses of IL-10 and IL-10/IL-6 ratio measurements have been proposed as diagnostic tools. Indeed, in PCNSL and PVRL, increased IL-10 levels in the vitreous or cerebrospinal fluids have been demonstrated [45–48]. Furthermore, the detection of an IL-10-to-IL-6 ratio greater than 1 in the vitreous and greater than 0.72 in the cerebrospinal fluid is considered useful for differentiating between PVRL and intraocular infectious diseases, and PCNL from intracranial infections, respectively [18, 48–52]. In the case of PVRL, this led to the suggestion for screening of suspected uveitis cases by evaluating IL-10 values and IL-10/IL-6 ratio before vitreous biopsy [53]. On the basis of our findings, IL-10 and IL-6 levels analysis may also be envisaged for late peri-implant seromas of the breast on the fluid undergoing cytological examination and microbiological culture. Indeed, cytokine measurement is a reliable and easy test that does not require additional special handling.

![Fig. 5](image)

**Fig. 5** Differential analysis among different conditions of the ratio of each cytokine concentration to IL-6 concentration. Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) versus all reactive seromas (RS) (a). BI-ALCL versus acute-type reactive seromas (RS-A) (b). BI-ALCL versus mixed-type reactive seromas (RS-M) (c). BI-ALCL versus chronic-type reactive seromas (RS-C) (d). T-cell lymphoma cell lines (T-LCL) versus RS (e). BI-ALCL versus T-LCL (f). BI-ALCL versus BI-ALCL-derived cell line (TLBR) (g). RS-A versus RS-M (h) and versus RS-M (i). RS-C versus RS-M (j). For each horizontal panel significant results are listed in the table in decreasing order of log-fold change (moderated t-statistics, adjusted p value <.01, BH procedure) and illustrated with a volcano plot in which the vertical dashed line correspond to fourfold up and down (+2, −2 on log2 scale) change, and the horizontal dashed line represents a p value of 0.01, such that all cytokines above this line are deemed statistical significant with respect to that cut-off. In both, tables and volcano plots, significant cytokines with p value <0.01 are indicated in red color, whereas those with p value <0.05 are in blue. Grey dots represent non-significant cytokines.

![Fig. 6](image)

**Fig. 6** IL-10 and IL-6 mRNA in CD30-positive BI-ALCL tumor cells. Immunohistochemistry for CD30 (red staining) and in situ hybridization for IL-6 and IL-10 mRNA (brown dots) in a BI-ALCL seroma (upper panel) and in a BI-ALCL xenografted onto an NGS mouse (lower panel) (original magnification ×400). CD30-positive tumor cells showed both IL-6 and IL-10 mRNA expression. In the neoplastic effusion the brown dots for IL-10 appeared more abundant than those for IL-6.
of the aspirated fluid or particular expertise in reading results. This approach, if appropriately validated in ad-hoc designed prospective studies with a cost-effective test, might represent a new diagnostic tool to support cytology in the screening of late seromas. In addition, the inclusion of even more rare breast implant-associated Epstein–Barr virus (EBV)-positive large B-cell lymphomas [54] would test the ability of the identified BI-ALCL-associated cytokine profile and of the IL-10/IL-6 value to discriminate between BI-ALCL and the EBV+ large B-cell lymphomas.

In conclusion, our results show that BI-ALCL has a distinctive cytokine profile, mainly characterized by high levels of IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio, which might represent additional biomarkers to be used in daily clinical practice for screening late seromas.

Acknowledgements

We thank Dr. Alan L. Epstein, MD PhD, for providing TLBR cell lines.

Author contributions

A. Di Napoli, M.E. Kadin, R. Mancini: conceptualization, methodology, writing, supervision, funding acquisition. D. Greco: data curation, formal analysis. G. Scafetta, F. Ascenzi, A. Gulino, L. Aurisicchio: investigation, visualization, validation. F. Santanelli Di Pompeo, A. Bonifacino, E. Giarnieri, J Morgan: resources.

Funding

Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement. This work has been supported by: Sapienza University project Ateneo 2017 to A. Di Napoli; Italian Association for Cancer Research (AIRC) grant n. IG17009, Lazioinnova grant n. 85-2017-13750 and Ministero dell’Istruzione, dell’Università e della Ricerca grant n. PRIN 2017 to R. Mancini; and Aesthetic Surgery Education and Research Foundation grant # 8580 to M.E. Kadin.

Availability of data

Luminex data can be found in a data supplement available with the online version of this article.
Compliance with ethical standards

Conflict of interest The authors declare no potential conflicts of interest.

Ethical approval The study was performed in accordance with the Declaration of Helsinki ethical guidelines for medical research involving human subjects and approved by the Ethics Committee of St. Andrea Hospital/University "Sapienza" of Rome (EC n. 82 SA, 2017) and Roger Williams Medical Center IRB (#18-522-99). The Animal Welfare Committee of the University of Rome Sapienza (Rome) in accordance with the European Guidelines for Animal Care and Use of Laboratory Animals approved all experiments with rodents (Project Authorization # A69/A0.2.EXT.12). All the procedures have been performed in accordance with "Directive 2010/63/EU on the protection of Animals used for scientific purposes" and made effective in Italy by the Legislative Decree DLGS 26/2014.

Informed consent Written informed consent was obtained from patients upon sample collection. Patients consented to the use of their specimens and data for research and publication.

Animal source Six-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG) obtained from Charles River were used in this work.

Cell line authentication Primary tumor cells derived from seromas of three patients diagnosed with BI-ALCL at St. Andrea Hospital, Roma, Italy were used in this work. Two out of 3 primary cultured cells were successfully authenticated using Short Tandem Repeat (STR) analysis by ATCC (n. STRA11550 and STRA11552). TLBR-1,2,3,4 are cell lines derived from clinical cases of BIA-ALCL and were kindly provided by Dr. Alan L. Epstein, MD PhD (Keck School of Medicine, University of Southern California). Mac-1, Mac-2A are cutaneous T cell lymphoma lines established by MEK and, Karpas 299 are an ALK-positive systemic ALCL line obtained from the DSMZ German Collection of Microorganisms and cell cultures GmbH. No cell line authentication was necessary.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Feldman AL, Harris NL, et al (2017) Breast implant-associated anaplastic large cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised. 4th ed: International Agency for Research on Cancer
2. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S et al (2016) Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 34(2):160–168
3. Clemens MW, Jacobsen ED, Horwitz SM (2019) NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J 39(Suppl. 1):S3–S13
4. Di Napoli A (2019) Achieving reliable diagnosis in late breast implant seromas: from reactive to anaplastic large cell lymphoma. Plast Reconstr Surg 143(3):SA Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma:15S–22S
5. Di Napoli A, Pepe G, Giarnieri E, Cippitelli C, Bonifacino A, Mattei M et al (2017) Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. PLoS ONE 12(7):e0181097
6. Kadin ME, Morgan J, Xu H, Gizikman CA (2017) CD30+ T cells in late Seroma may not be diagnostic of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J 37(7):771–775
7. Hanson SE, Hassid VJ, Branch-Brooks C, Liu J, Kadin ME, Miranda R et al (2020) Validation of a CD30 enzyme-linked immunosorbent assay for the rapid detection of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J 40(2):149–153
8. Kadin ME, Morgan J, Koutab N, Xu H, Adams WP, Gizikman C, malignant and benign effusions around breast implants. Aesthet Surg J 40(6):630–637
9. Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB et al (2012) Survival signals and targets for therapy in breast implant-associated ALK–anaplastic large cell lymphoma. Clin Cancer Res 18(17):4549–4559
10. Murtagh F, Legendre P (2014) Ward’s hierarchical agglomerative clustering method: which algorithms implement ward’s criterion? J Classif 31(3):274–295
11. Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32(18):2847–2849
12. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. https://doi.org/10.2202/1544-6115.1027
13. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e17
14. Benjamini Y, Drai D, Elmer G, Kaafarani N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1–2):279–284
15. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77
16. Pepe G, Di Napoli A, Cippitelli C, Scarpino S, Pilozzi E, Ruco L (2018) Reduced lymphotxin-beta production by tumour cells is associated with loss of follicular dendritic cell phenotype and diffuse growth in follicular lymphoma. J Pathol Clin Res 4(2):124–134
17. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A et al (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14(1):22–29
18. Pochat-Cottiloux C, Bienvenu J, Nguyen AM, Ohanesian R, Ghesquieres H, Sepe P et al (2018) Use of a threshold of interleukin-10 and II-10/II-6 ratio in ocular samples for the screening of vitreoretinal lymphoma. Retina 38(4):773–781
19. Kadin ME, Morgan J, Xu H, Epstein AL, Sieber D, Hubbard BA et al (2018) IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. Hum Pathol 78:64–62
20. Di Napoli A, De Cecco L, Piccaluga PP, Navari M, Cancila V, Cippitelli C et al (2019) Transcriptional analysis distinguishes Cancer Immunology, Immunotherapy
breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. Mod Pathol 32(2):216–230

21. Di Napoli A, Jain P, Duranti E, Margol skee E, Arancio W, Facchet ti F et al (2018) Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. Br J Haematol 180(5):741–744

22. Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF et al (2016) Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica 101(9):e387–e390

23. Letourneau A, Maerevoet M, Milowich D, Dewind R, Bisig B, Missia gilia E et al (2018) Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma. Vir chows Arch 473(4):505–511

24. Oishi N, Miranda RN, Feldman AL (2019) Genetics of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J 39(Suppl_1):14–20

25. Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME et al (2016) Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg 137(6):1659–1669

26. Muñoz-Carrillo JL, Cordero JFC, Gutiérrez-Coronado O, Vil lalobos-Gutiérrez PT, Ramos-Gracia LG, Hernández-Reyes VE (2019) Cytokine profiling plays a crucial role in activating immune system to clear infectious pathogens. In: Immune Response Activation and Immunomodulation. London, UK: IntechOpen (2018). https://doi.org/10.5772/intechopen.80843

27. Paul WE, Zhu J (2010) How are (H)2-type immune responses initiated and amplified? Nat Rev Immunol 10(4):225–235

28. Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR (2017) Interleukin-13 in asthma and other eosinophilic disorders. Front Med (Lausanne) 4:139

29. O’Reilly S (2013) Role of interleukin-13 in fibrosis, particularly systemic sclerosis. BioFactors 39(6):592–596

30. Goswani R, Kaplan MH (2011) A brief history of IL-9. J Immunol 186(6):3283–3288

31. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi G, Vina J et al (2009) IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A 106(31):12885–12890

32. Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie AN et al (2011) IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 186(1):83–91

33. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D et al (2006) Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108(7):2407–2415

34. Glimelius I, Edstrom A, Amini RM, Fischer M, Nilsson G, Sundstrom C et al (2006) IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 76(4):278–283

35. Gutierrez-Ramos JC, Lloyd C, Gonzalo JA (1999) Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today 20(11):500–504

36. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267(2):271–285

37. Jundt F, Anagnostopoulos I, Bonmert K, Emmerich F, Muller G, Foss HD et al (1999) Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 94(6):2065–2071

38. Lauren C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L et al (2016) Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol 27(2):306–314

39. Gramaglia I, Mauri DN, Miner KT, Ware CF, Croft M (1999) Lymphotoxin alphabeta is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation. J Immunol 162(3):1333–1338

40. Morel PA, Oriss TB (1998) Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 18(4):275–303

41. Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180(9):5771–5777

42. Ouyang W, Rutz S, Crelin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109

43. Wan YY, Flavell RA (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445(7129):766–770

44. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA (2009) Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 21(3):281–285

45. Sasayama T, Nakamizo S, Nishihara M, Kawamura A, Tanaka H, Mizukawa K et al (2012) Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol 14(3):368–380

46. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L et al (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121(23):4740–4748

47. Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Chou ket S, Benanni H et al (2016) The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer 61:69–76

48. Whitcup SM, Stark-Vancs W, Wittes RE, Solomon D, Podgor MJ, Nussenblatt RB et al (1997) Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 115(9):1157–1160

49. Buggage RR, Whitcup SM, Nussenblatt RB, Chan CC (1999) Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. Invest Ophthalmol Vis Sci 40(10):2462–2463

50. Wolf LA, Reed GF, Buggage RR, Nussenblatt RB, Chan CC (2003) Vitreous cytokine levels. Ophthalmology 110(8):1671–1672

51. Song Y, Zhang W, Zhang L, Wu W, Zhang Y, Han X et al (2016) Cerebrospinal fluid IL-10 and IL-10R1/6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma. Sci Rep 6:38671

52. Chan CC (2003) Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc 101:275–292

53. Frenkel S, Pe’er J, Kaufman R, Maly B, Habot-Wilner Z (2020) The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma. Acta Ophthalmol. https://doi.org/10.1111/aos.14347

54. Rodriguez-Pinilla SM, Sanchez-Garcia EJ, Balague O, Rodriguez-Justo M, Piris MA (2019) Breast implant-associated EBV-positive large B-cell lymphomas: report of three cases. Haematologica. https://doi.org/10.3324/haematol.2019.232355

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.